Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
Katherine A. Minson, Catherine C. Smith, Deborah DeRyckere, et al.
JCI Insight (2016) Vol. 1, Iss. 3
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Drugging the efferocytosis process: concepts and opportunities
Parul Mehrotra, Kodi S. Ravichandran
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 8, pp. 601-620
Open Access | Times Cited: 204
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter, Katie Hege, Jay Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 165
A review of FLT3 inhibitors in acute myeloid leukemia
Jennifer Zhao, Sonal Agarwal, Hiba Ahmad, et al.
Blood Reviews (2021) Vol. 52, pp. 100905-100905
Open Access | Times Cited: 122
TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 46
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Justus M. Huelse, Diana Fridlyand, Shelton Earp, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107577-107577
Open Access | Times Cited: 71
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
Agnete S.T. Engelsen, Maria L. Lotsberg, Raefa Abou Khouzam, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
Sherri K. Smart, Eleana Vasileiadi, Xiaodong Wang, et al.
Cancers (2018) Vol. 10, Iss. 12, pp. 474-474
Open Access | Times Cited: 80
MerTK as a therapeutic target in glioblastoma
Jing Wu, Lauren N. Frady, Ryan Bash, et al.
Neuro-Oncology (2017) Vol. 20, Iss. 1, pp. 92-102
Open Access | Times Cited: 70
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar, Morgan M. Walker, LaQuita M. Jones, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 508
Open Access | Times Cited: 68
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
Alisa B. Lee‐Sherick, Kristen M. Jacobsen, Curtis J. Henry, et al.
JCI Insight (2018) Vol. 3, Iss. 21
Open Access | Times Cited: 67
UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
Deborah DeRyckere, Alisa B. Lee‐Sherick, Madeline G. Huey, et al.
Clinical Cancer Research (2016) Vol. 23, Iss. 6, pp. 1481-1492
Open Access | Times Cited: 64
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Motoki Eguchi, Yosuke Minami, Ayumi Kuzume, et al.
Biomedicines (2020) Vol. 8, Iss. 8, pp. 245-245
Open Access | Times Cited: 57
TAM Receptor Inhibition–Implications for Cancer and the Immune System
Pia Aehnlich, Richard Powell, Marlies J. W. Peeters, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1195-1195
Open Access | Times Cited: 55
Therapeutic targeting of the functionally elusive TAM receptor family
Yu Rebecca Miao, Erinn B. Rankin, Amato J. Giaccia
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 3, pp. 201-217
Open Access | Times Cited: 19
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
Gabriel Ghiaur, Mark J. Levis
Hematology/Oncology Clinics of North America (2017) Vol. 31, Iss. 4, pp. 681-692
Open Access | Times Cited: 57
Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia
Carly Campbell, Jessica N. Haladyna, David A. Drubin, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 8, pp. 1669-1679
Open Access | Times Cited: 53
MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
Dan Yan, Justus M. Huelse, Dmitri Kireev, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 15
Open Access | Times Cited: 26
Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment
Joselyn Cruz Cruz, Kristen C. Allison, Lauren S. Page, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia
Jiasheng Wang, Benjamin Tomlinson, Hillard M. Lazarus
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 7, pp. 770-801
Closed Access | Times Cited: 14
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
Melisa Tecik, Aysun Adan
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1449-1478
Open Access | Times Cited: 22
“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
Tristan Knight, Holly Edwards, Soheil Meshinchi, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3398-3398
Open Access | Times Cited: 20
Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment
Guoqiang Zhu, Xinliang Wan, Wanyin Wu, et al.
Small Science (2025)
Open Access
Targeting the TAM Receptors in Leukemia
Madeline G. Huey, Katherine A. Minson, H. Shelton Earp, et al.
Cancers (2016) Vol. 8, Iss. 11, pp. 101-101
Open Access | Times Cited: 34
Phosphatidylserine receptor-targeting therapies for the treatment of cancer
Miso Park, Keon Wook Kang
Archives of Pharmacal Research (2019) Vol. 42, Iss. 7, pp. 617-628
Closed Access | Times Cited: 32
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Dan Yan, H. Shelton Earp, Deborah DeRyckere, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5639-5639
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top